You should know exactly what is (and isn't) in the bottle
2024;14(3):e3448
Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies
For vaginal complaints, a pragmatic approach consistent with pharmacovigilance principles is: Continue semaglutide while treating common causes unless symptoms are severe, refractory, temporally tightly linked to dosing/escalation, and alternative diagnoses have been reasonably excluded
Lau DCW, Erichsen L, Francisco AM, et al
Among the most frequent adverse effects are: vomiting, nausea, diarrhea, hypoglycemia in case of use with oral diabetes medications other than sulfonylureas or insulin, gastritis, stomach pain, fatigue, constipation, dizziness, retinopathy